Quince Therapeutics, Inc. QNCX 深 沪
已收盘 02-06 16:00:00 美东时间
0.1391
-0.007
-4.79%
华盛通- 最 高0.146
- 今 开0.146
- 成交量 494.46万股
- 最 低 0.1333
- 昨 收 0.1461
- 总市值 774.53万
- 52周最高 4.5499
- 市盈率 静 --
- 换手率 8.88%
- 52周最低 0.1333
- 委 比 51.06%
- 总股本 5568.15万
- 历史最高 121.98
- 量 比 0.40
- 振 幅 8.69%
- 历史最低 0.1333
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quince Therapeutics Announces Significant Board of Directors Resignations
An update from Quince Therapeutics ( ($QNCX) ) is now available. On January 30,...
02-03 06:11
Five Directors Resign from Quince Therapeutics Board
Five Directors Resign from Quince Therapeutics Board Quince Therapeutics Inc. announced that Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray have resigned from the company's board of directors, effective January 30, 2026. The company stated that the resignations were not due to
02-03 05:31
D. Boral Capital Downgrades Quince Therapeutics to Hold
D. Boral Capital analyst Jason Kolbert downgrades Quince Therapeutics (NASDAQ:QNCX) from Buy to Hold.
01-30 20:45
美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Quince Therapeutics Announced The Poster Presentation From The Long-term Treatment Of Children With Ataxia-Telangiectasia At The British Paediatric Neurology Association 2026 Annual Meeting; Long-term Treatment With eDSP In Children With A-T Was Associated With Stable Growth And Metabolic Parameters Without Indications Of Corticosteroid-Related Toxicities
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of
01-29 05:30
Quince Therapeutics Reports Long-Term Safety Data for eDSP in Children with Ataxia-Telangiectasia
Quince Therapeutics Reports Long-Term Safety Data for eDSP in Children with Ataxia-Telangiectasia Quince Therapeutics Inc. announced the presentation of previously published safety data from long-term treatment with encapsulated dexamethasone sodium phosphate (eDSP) in children with Ataxia-Telangiec
01-29 05:06
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Quince Therapeutics Says Last Patient Completed Last Visit In Pivotal Phase 3 NEAT Clinical Trial Of eDSP, In Patients With Ataxia-Telangiectasia; Expects To Report Topline Results From In Q1 2026
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has
2025-12-15 21:07
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - December ...
2025-11-29 02:30
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
